Biting The Dust -- Is Lipicard's Niastin(R) Next After Pfizer's Torcetrapib?HYDERABAD, India -- With dramatic discontinuation of Torcetrapib development by Pfizer, questions are raised about other new therapies targeting HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. increase including Lipicard's Niastin - combination of novel NCE's for integrated Cholesterol Management. Niastin[R] is the latest drug being developed for Integrated Cholesterol Management through Lipicard's novel platform technology for producing high therapeutic index drugs - drugs that are safer and more efficacious. Prasad Prasāda (Sanskrit: प्रसाद), prasād/prashad (Hindi), Prasāda in (Kannada), prasādam (Tamil), or prasadam Sambaru CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Lipicard talking on the dramatic events of Torcetrapib said that it is very unfortunate that Pfizer has to end the development of Torcetrapib after incurring such huge costs. He lauded the way Pfizer has handled the Torcetrapib situation. He also added that developments at Pfizer will not have any effect on Niastin developments as the mechanism of action of Niastin and Torcetrapib are totally different, in fact, Niastin program has been put on fast track after the withdrawal of Torcetrapib by Pfizer. The lipid management and control is effected through a two pronged attack - first reducing LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. and total cholesterol using Statins, and the other is to increase the HDL Cholesterol using Niacin niacin: see coenzyme; vitamin. niacin or nicotinic acid or vitamin B3 Water-soluble vitamin of the vitamin B complex, essential to growth and health in animals, including humans. etc. Both Statins and Niacin also increase the HDL and reduce the LDL, VLDL VLDL very-low-density lipoprotein. ß-VLDL , beta VLDL a mixture of lipoproteins with diffuse electrophoretic mobility approximately that of ß-lipoproteins but having lower density; they are remnants derived from respectively, but predominantly Statins decrease LDL and Niacin increases HDL. Niastin[R] is combination of novel NCE's for increasing the HDL as well as reducing the LDL and VLDL lipoproteins. When compared to Niacin and Statin combination drugs in the market, Niastin is expected to be more efficacious with less toxic side effects including muscle and liver toxicity and flushing. Niastin[R] is being produced using the same novel platform technology that produced the other high therapeutic drugs - Platrol[R] (Safe Antiplatelet drug), KeraKlear[R] (Safe and clear solution for Keratoconjuctivities), etc. About Lipicard Technologies: Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . USA. PLATROL[R] is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug Niastin for increasing HDL and lowering LDL, and safe NSAIDs. PLATROL[R] is registered trademarks of Life Enhancing Technologies. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion